Bropirimine
Bropirimine is a synthetic agonist for toll-like receptor 7 (TLR7). Bropirimine inhibits differentiation of osteoclast precursor cells into osteoclasts via TLR7-mediated production of IFN-β. Bropirimine is an orally active immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary tract[1][2].
| Trivial name | / |
| Catalog Number | CSN25419 |
| Alternative Name(s) | / |
| Research Area | Immunology/Inflammation|Cancer |
| Molecular Formula | C10H8BrN3O |
| CAS# | 56741-95-8 |
| Purity | ≥99% |
| SMILES | C1=CC=CC=C1C2=C(C(N=C(N2)N)=O)Br |
| Size | 100mg |
| Supplier Page | https://www.csnpharm.com/products/bropirimine.html |